FASN and cancer: Additionally, an increase in de novo fatty acid biogenesis is a metabolic attribute that equips tumours with proliferative and survival benefits, and therefore, FASN (fatty acid synthase) is overexpressed in many cancers, including colon cancer (Schroeder et al. 2021).